1.Clinical Significance of Phase Analysis in Myocardial Infarction.
Hyun Seung KIM ; Je Yol OH ; Hyuck Moon KWON ; Yang Soo JANG
Korean Circulation Journal 1992;22(1):67-76
BACKGROUND: Evaluating the segmental wall motion of left ventricle is important in patients with myocardial infarction for choosing therapeutic modality and predicting prognosis. Radionuclide Multigated Angiography(MUGA) is a reliable noninvasive method for the evaluation of left ventricular performance. Methods : MUGA scan(LV ejection fraction, phase image histogram, regional wall motion) was performed and analyzed in 45 patients with myocardial infarction(31 : acute MI, 14: old MI) and 13 normal controls. RESULTS: 1) The LVEF of acute and old MI group was significantly reduced and the SDph of acute and old MI group was significantly increased as compared with that of control group(p<0.05). 2) In acute MI group, the LVEF of group without, IV Urokinase was more reduced than that of group with IV Urokinase and the SDph of group without IV Urokinase was more increased than that of group with IV Urokinase(p<0.05). As a result of wall motion scoring, the linear correlation exists between SDPh and sum of wall motion scoring(r=0.62, p<0.01). 3) In MI group, the LVEF of anterior wall MI was more reduced than that of inferior wall MI and the SDPh of anterior wall MI was more increased than that of inferior wall MI(p<0.05). 4) In acute anterior wall MI, the reverse correlation exists between LVEF and SDPh and the linear correlation exists between sum of wall motion scoring and SDPh(r=-0.73, 0.72, p<0.01). But there are no statistical significances of correlation between them in acute inferior MI(r=-0.44, 0.42, p>0.05), in old anterior MI(r=-0.65, 0.47, p>0.05) and in old inferior MI(r=-0.47, 0.46, P>0.05). CONCLUSION: These results suggest that Phase angle(SDPh) is thought to be valuable index to evaluate left ventricular function with application of other indeces in Myocardial infarction. Left ventricular function measured by SDph in acute or anterior MI is lower than old or inferior MI.
Heart Ventricles
;
Humans
;
Myocardial Infarction*
;
Prognosis
;
Urokinase-Type Plasminogen Activator
;
Ventricular Function, Left
2.Selective arterial embolization of renal arteriovenous fistula after renal biopsy : A case report and review of litertures.
Kyeong Mi LEE ; Je Yol OH ; Jong Hun PARK ; U Chang CHOI ; Sung Kyu HA ; Dong Ik KIM ; Ki Whang KIM
Korean Journal of Nephrology 1993;12(2):194-198
No abstract available.
Arteriovenous Fistula*
;
Biopsy*
3.Clinical significance of renal resistive index(RI) in diabetic patients.
Je Yol OH ; Han Sun CHO ; Sung Kyu HA ; Ho Yung LEE ; Dae Suk HAN ; Kyung Rae KIM ; Ki Whang KIM ; Yeon Hee LEE
Korean Journal of Nephrology 1993;12(2):144-150
No abstract available.
Humans
4.Paragonimiasis.
Je Yol OH ; Chul Min AHN ; Tae Sun KIM ; Eui Suk HWANG ; Hyung Jung KIM ; Sung Kyu KIM ; Won Young LEE
Tuberculosis and Respiratory Diseases 1992;39(1):103-108
No abstract available.
Paragonimiasis*
5.Gastric cancer associated with pregnancy.
Joon Han SHIN ; Je Yol OH ; Hyo Jin PARK ; Jun Pyo CHUNG ; Kwan Sik LEE ; Sang In LEE ; In Suh PARK ; Heung Jae CHOI
Korean Journal of Medicine 1993;45(1):84-91
No abstract available.
Pregnancy*
;
Stomach Neoplasms*
6.Carcinosarcoma of the lung.
Kyeong Mi LEE ; Seon Og KWEON ; Je Yol OH ; Eui Suk HWANG ; Hyung Jung KIM ; Chul Min AHN ; Sung Kyu KIM ; Won Young LEE ; Sang Jin KIM ; Kyi Beom LEE
Korean Journal of Medicine 1993;45(2):270-276
No abstract available.
Carcinosarcoma*
;
Lung*
7.Phase II trial of 5-FU, etoposide, cisplatin (FEP) combination chemotherapy in unresectable non-small cell lung cancer.
Jin Hyuk CHOI ; Hyun Cheol CHUNG ; Dong Jip KIM ; Je Yol OH ; Joon CHANG ; Eun Hee KOH ; Joo Hang KIM ; Jae Kyung RHO ; Sung Kyu KIM ; Won Young LEE ; Gwi Eon KIM ; John Kyu LOH JUHN
Journal of the Korean Cancer Association 1991;23(1):120-130
No abstract available.
Carcinoma, Non-Small-Cell Lung*
;
Cisplatin*
;
Drug Therapy, Combination*
;
Etoposide*
;
Fluorouracil*
8.Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Overview and Summary 2024
Young Joo PARK ; Eun Kyung LEE ; Young Shin SONG ; Bon Seok KOO ; Hyungju KWON ; Keunyoung KIM ; Mijin KIM ; Bo Hyun KIM ; Won Gu KIM ; Won Bae KIM ; Won Woong KIM ; Jung-Han KIM ; Hee Kyung KIM ; Hee Young NA ; Shin Je MOON ; Jung-Eun MOON ; Sohyun PARK ; Jun-Ook PARK ; Ji-In BANG ; Kyorim BACK ; Youngduk SEO ; Dong Yeob SHIN ; Su-Jin SHIN ; Hwa Young AHN ; So Won OH ; Seung Hoon WOO ; Ho-Ryun WON ; Chang Hwan RYU ; Jee Hee YOON ; Ka Hee YI ; Min Kyoung LEE ; Sang-Woo LEE ; Seung Eun LEE ; Sihoon LEE ; Young Ah LEE ; Joon-Hyop LEE ; Ji Ye LEE ; Jieun LEE ; Cho Rok LEE ; Dong-Jun LIM ; Jae-Yol LIM ; Yun Kyung JEON ; Kyong Yeun JUNG ; Ari CHONG ; Yun Jae CHUNG ; Chan Kwon JUNG ; Kwanhoon JO ; Yoon Young CHO ; A Ram HONG ; Chae Moon HONG ; Ho-Cheol KANG ; Sun Wook KIM ; Woong Youn CHUNG ; Do Joon PARK ; Dong Gyu NA ;
International Journal of Thyroidology 2024;17(1):1-20
Differentiated thyroid cancer demonstrates a wide range of clinical presentations, from very indolent cases to those with an aggressive prognosis. Therefore, diagnosing and treating each cancer appropriately based on its risk status is important. The Korean Thyroid Association (KTA) has provided and amended the clinical guidelines for thyroid cancer management since 2007. The main changes in this revised 2024 guideline include 1) individualization of surgical extent according to pathological tests and clinical findings, 2) application of active surveillance in low-risk papillary thyroid microcarcinoma, 3) indications for minimally invasive surgery, 4) adoption of World Health Organization pathological diagnostic criteria and definition of terminology in Korean, 5) update on literature evidence of recurrence risk for initial risk stratification, 6) addition of the role of molecular testing, 7) addition of definition of initial risk stratification and targeting thyroid stimulating hormone (TSH) concentrations according to ongoing risk stratification (ORS), 8) addition of treatment of perioperative hypoparathyroidism, 9) update on systemic chemotherapy, and 10) addition of treatment for pediatric patients with thyroid cancer.